<DOC>
	<DOCNO>NCT00997997</DOCNO>
	<brief_summary>This international , prospective , non-interventional , non-controlled observational study obtains data efficacy , safety tolerability Avelox treatment daily-life treatment condition . Specifically investigated improvement clinical symptom duration infection improvement cure.Any patient diagnosis complicate skin skin structure infection ( cSSSI ) treat Avelox document . The observation period subject cover treatment period Avelox . For patient , physician document data initial visit one two follow-up visit ( ) line routine practice .</brief_summary>
	<brief_title>Avelox Complicated Skin Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Any patient diagnosis complicate skin skin structure infection ( cSSSI ) decision make attend physician start treatment Avelox inclusion independent study . Exclusion criterion specify local product information .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Skin Diseases , Bacterial</keyword>
	<keyword>Product Surveillance</keyword>
	<keyword>Postmarketing</keyword>
</DOC>